Albireo Pharma, Inc. (ALBO) Receives Average Rating of “Hold” from Brokerages
Shares of Albireo Pharma, Inc. (NASDAQ:ALBO) have received an average recommendation of “Hold” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $71.00.
Several equities research analysts have issued reports on ALBO shares. Zacks Investment Research raised shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Tuesday, January 16th. BidaskClub raised shares of Albireo Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, January 31st. Wedbush reissued a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, January 3rd. Cowen reissued a “buy” rating on shares of Albireo Pharma in a research report on Friday, November 17th. Finally, Roth Capital started coverage on shares of Albireo Pharma in a research report on Wednesday, November 15th. They issued a “buy” rating and a $92.00 price objective for the company.
In related news, major shareholder Life Sciences Maste Perceptive acquired 275,000 shares of the stock in a transaction on Thursday, January 25th. The stock was bought at an average cost of $33.00 per share, with a total value of $9,075,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Phase4 Partners Ltd sold 100,000 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $34.44, for a total transaction of $3,444,000.00. The disclosure for this sale can be found here. 22.30% of the stock is owned by insiders.
Shares of Albireo Pharma (ALBO) opened at $35.39 on Friday. Albireo Pharma has a 52-week low of $15.31 and a 52-week high of $39.87.
About Albireo Pharma
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.